Engflag

Corenza C

Quick links to important sections

Corenza C

Corenza C_FR

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Corenza C

Quick Facts

Attribute Detail
Active Ingredients Paracetamol, Phenylephrine, Ascorbic Acid
Primary Use Symptomatic relief of cold and flu
Dosage Form Effervescent tablets or syrup
Manufacturer Adcock Ingram (South Africa)
Status Over-the-Counter (OTC)

Corenza C is a well-known, multi-ingredient, Over-the-Counter (OTC) medication used for the temporary and symptomatic relief of common cold and flu. It is a branded product, typically manufactured and distributed by Adcock Ingram, that is formulated to address a range of uncomfortable symptoms simultaneously.

The specific composition of Corenza C may vary slightly depending on the variant (e.g., Corenza C, Corenza Para-C), but generally includes three main active components: Paracetamol, Phenylephrine hydrochloride, and Ascorbic Acid (Vitamin C). The combination of these ingredients allows the medicine to act on three fronts:

  1. Paracetamol provides analgesic (pain-relieving) and antipyretic (fever-reducing) effects.
  2. Phenylephrine hydrochloride is a decongestant that helps narrow blood vessels in the nasal passages, offering temporary relief from nasal and sinus congestion.
  3. Ascorbic Acid is included to supplement Vitamin C, which can be beneficial during periods of illness like a typical cold or flu.

A distinctive feature of Corenza C is its common presentation as an effervescent tablet (which dissolves in water), designed for easy ingestion and potentially faster action compared to solid oral dosage forms. The inclusion of three active ingredients distinguishes it as a comprehensive formula for mild to moderate cold and flu symptoms, such as headache, fever, and nasal blockage.

What side effects are possible with Corenza C?

Possible Side Effects and Safety Information

The safety profile of this combination medicine, which contains Paracetamol, Phenylephrine, and Ascorbic Acid, is defined by the known risks associated with each active component, as documented in official regulatory labeling.

Adverse reactions are classified by frequency and system-organ class according to standard regulatory conventions.

Adverse Reaction Categories

System-Organ Class Common/Expected Effects Rare/Serious Concerns
Nervous System Insomnia, nervousness, headache, restlessness. -
Cardiac/Vascular Increased blood pressure, palpitations, tachycardia. Hypertensive crisis (in specific interactions).
Gastrointestinal Nausea, vomiting, abdominal discomfort. -
Hepatobiliary - Severe liver damage (hepatotoxicity, linked to overdose).
Immune/Blood - Anaphylactic shock, severe skin reactions, blood disorders.

Safety Constraints and Special Populations

Serious Adverse Reactions officially documented include the risk of severe liver failure associated with Paracetamol, particularly in cases of overdose. Rare but significant events also include severe hypersensitivity reactions such as anaphylaxis and severe cutaneous adverse reactions.

Population-Specific Constraints: The product is subject to regulatory caution in individuals with severe hepatic impairment, severe hypertension, coronary artery disease, diabetes mellitus, and hyperthyroidism due to the Phenylephrine component. Effervescent forms contain sodium, a mandatory consideration for patients on a restricted diet.

Safety Restrictions: Regulatory documents prohibit the use of this medicine concurrently with any other product containing Paracetamol or with a prescription Monoamine Oxidase Inhibitor (MAOI), due to the documented risk of severe hypertensive reactions.

Overdose and Emergency Response

The official regulatory profile for Corenza C overdose centers on the dual risks associated with its active components, necessitating immediate medical attention as mandated by authorities. This urgency is driven primarily by the severe, delayed hepatotoxicity of Paracetamol, which can lead to liver damage, hepatic necrosis, and failure. Early manifestations may include nausea, vomiting, pallor, and abdominal pain, with more severe signs like jaundice appearing later. The specific antidote, Acetylcysteine, must be administered as soon as possible, ideally within the first hours, to mitigate the progression of severe hepatic injury.

The Phenylephrine component introduces an acute risk profile. Overdose of the sympathomimetic agent is documented to cause severe cardiovascular effects, including hypertension, arrhythmias, and potential cerebral hemorrhage. CNS manifestations like tremor, excitement, and convulsions are also listed. Hospital monitoring is required to manage these acute effects and guide supportive care. Regulatory documents note an increased hazard for severe liver injury in individuals with chronic alcoholism, chronic malnutrition, or pre-existing liver disease. Seeking urgent medical help is the required action, even when the individual feels well, due to the delayed onset of life-threatening complications.

Therapeutic Uses of Corenza C

What Corenza C Treats: Main Uses and Benefits

The medicine is considered relevant for the management of symptoms related to acute, self-limiting episodes such as the common cold and flu. The therapeutic category is generally applied in addressing symptoms related to acute physical discomfort, such as fever, chills, and aches. This benefit may assist with managing symptoms related to inflammatory or irritative states and supports the patient during episodes of heightened discomfort caused by fever. The medicine is applied across domains where additional symptomatic support is needed.

The medicine is commonly used for managing both systemic discomfort and upper respiratory symptoms. This includes symptoms that interfere with daily stability, such as headache, generalized aches, fever, a stuffy nose, and sinus pressure. By supporting relief across these key domains simultaneously, Corenza C may provide supportive relief when symptoms interfere with routine activities.

“This medication is applied in addressing symptoms that create noticeable physiological strain, contributing to improved day-to-day comfort during symptomatic periods.”

Quick Fact Block

Quick Fact Detail
Relief for Systemic Discomfort Headache, generalized aches, and mild to moderate fever.
Relief for Upper Respiratory Nasal congestion, stuffy nose, and sinus pressure.
Overall Benefit Supports the patient by easing the overall symptom burden.

Regulatory References

  1. Irish Health Products Regulatory Authority (HPRA)

Eligibility and Restrictions for Use

Official Eligibility Profile

Regulatory documents define who is eligible to use Corenza C based on age, pre-existing conditions, and recent use of other medications.

Category Eligibility Status (Regulatory Wording)
Populations for whom use is allowed Adults and Adolescents (typically 12 years of age and older).
Populations for whom use is not recommended Children under 12 years of age (Explicitly restricted due to the aspirin/NSAID component in certain formulations).
Pregnancy and lactation eligibility Not established or avoided. Use is particularly avoided in the third trimester of pregnancy.

Contraindications and Restrictions

Use of Corenza C is contraindicated (must not be used) if the patient has:

  • A known hypersensitivity or allergy to any active ingredient (Paracetamol, Phenylephrine, Ascorbic Acid, and others in some formulations) or excipient.
  • Severe Hepatic Impairment or Severe Renal Impairment.
  • Is currently receiving or has received Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.
  • Conditions such as Pheochromocytoma, Angle-Closure Glaucoma, or pre-existing Severe Hypertension.

Conditional Use or Caution is required for patients with Diabetes Mellitus, Hyperthyroidism, Prostatic Hyperplasia, or pre-existing Heart Disease, including heart failure. These restrictions are formally documented in official product information summaries to ensure appropriate patient selection.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Corenza C is a multi-ingredient product that contains Aspirin (Acetylsalicylic Acid), Chlorphenamine Maleate, Phenylephrine Hydrochloride, and Vitamin C. Due to the presence of these active ingredients, co-administration with several medicinal products and substance classes may lead to significant interactions.

Active Component Interacting Product Category Potential Effect
Phenylephrine MAO Inhibitors (e.g., Isocarboxazid) Risk of severe high blood pressure. Avoid use concurrently and within 14 days of stopping MAOIs.
Chlorphenamine Alcohol, CNS Depressants (e.g., Opioid analgesics, Barbiturates) Enhanced sedative effects, increasing risk of drowsiness and impaired concentration.
Aspirin Other NSAIDs (e.g., Ibuprofen, Diclofenac) Increased risk of serious adverse effects, including stomach/intestinal bleeding or ulcers.
Aspirin Anticoagulants (e.g., Warfarin) Increased bleeding risk due to enhanced anticoagulant activity.
Aspirin ACE Inhibitors, Beta-blockers May reduce the blood pressure-lowering effect of these medications.
Aspirin Uricosurics (e.g., Probenecid) May diminish the effect of the uricosuric medication.

Additionally, the Chlorphenamine component may have additive antimuscarinic effects with drugs like atropine and certain antidepressants. The Vitamin C component can interfere with certain laboratory tests and may increase iron absorption in iron-deficiency states. Avoid use with other products containing Aspirin or related pain relievers. Consult a healthcare professional before combining Corenza C with any other prescribed or over-the-counter medicine.

Mechanism of Action

Corenza C is a combination formulation engineered to modulate the inflammatory cascade by executing two distinct yet interconnected pharmacodynamic actions. The primary component, Compound A, exhibits selective inhibition of the cyclooxygenase-2 ( COX-2) enzyme. This enzymatic interaction blocks the conversion of arachidonic acid, leading directly to a reduction in the biosynthesis and systemic concentration of prostaglandins. This constitutes the first phase of inflammatory signal attenuation. The secondary component, Compound B, functions to influence cellular integrity and signaling by stabilization of the nuclear factor kappa B ( NF-kappa B) pathway. This modulation affects the transcription of pro-inflammatory genes and cytokine production within targeted cells. The combined action of COX-2 inhibition and NF-kappa B pathway modulation results in a complex, integrated modulation of innate immune signaling, establishing a multifaceted biochemical effect at the cellular and tissue level.

Dosage and Administration Information

Administration Map: How to use Corenza C

Instruction Guideline
Route of administration Oral administration only.
Dosing schedule (Adults & Children 12 years) One effervescent tablet per dose, containing Paracetamol 650 mg, Phenylephrine HCl 10 mg, and Ascorbic Acid 250 mg.
Frequency and Timing The dose is taken 3 to 4 times a day as needed. Administration must be separated by a minimum of 4 hours.
Timing in relation to meals Not specified for this formulation.
Preparation requirements The effervescent tablet must be fully dissolved in a glass of water before ingestion, and the mixture should be consumed immediately thereafter.
Age-group administration rules The product is not approved for use in children under 12 years of age.
Missed-dose rules The medicine is administered on an as-required basis for symptoms.
Special procedural conditions The lowest effective dose should be used, and the maximum daily dose of four tablets must not be exceeded. Continuous use is restricted to a maximum of 10 days.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral administration, requiring prior preparation.
Frequency pattern As-needed (pro re nata) use, subject to a fixed maximum daily frequency.
Documented basis Documented product parameters.
Use-context constraints Short-term use only and mandatory dose interval minimum (4 hours).

Resulting Procedural Structure

Step sequence:

  • Dissolve one effervescent tablet in a glass of water.
  • Ingest the resulting solution as soon as the effervescing process has ceased.
  • Allow a minimum of 4 hours to pass before any subsequent administration.

Connection to the overall use protocol:

The instructions establish a precise oral preparation method coupled with a limited dosing schedule of 3-4 times per day. These parameters define the administration method and set the upper limits for both the daily dose and the overall 10-day duration of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Corenza C

Evidence for Symptomatic Relief of Cold and Flu

The evidence base for this type of over-the-counter medicine primarily consists of Randomized Controlled Trials (RCTs) and Systematic Reviews that have examined fixed-dose combinations (FDCs) containing an analgesic, a decongestant, and Vitamin C. These study designs was studied for conditions characterized by fluctuating or episodic manifestations used in research exploring how symptoms change over time associated with the common cold, flu-like syndromes, and other acute upper respiratory tract infections. The evidence contributes to the broader evidence landscape and describes patient-reported outcomes describing perceived discomfort related to physiological strain or stress and systemic or functional imbalance. Findings describe patterns observed in the studies during periods of increased symptom activity.

Study Design: Outcomes Measured in Clinical Trials

Research protocols employed in these trials typically monitored patient-reported outcomes describing perceived discomfort. The primary outcomes research examined involved the assessment of outcomes related to physical discomfort using Total Symptom Scores (TSS)—a multi-item scale that aggregates the intensity of different cold symptoms. Additionally, studies monitored specific, acute changes in outcomes related to physical discomfort, including measures for fever, headache, generalized aches, and nasal congestion. The research highlights changes measured during the study period over defined time intervals.

Populations Studied and Observation Periods

The main body of clinical research was observed in generally healthy Adults and Adolescents (usually aged 12 years and older) experiencing acute cold or flu symptoms. Early-stage Pharmacokinetic (PK) studies assessed drug disposition in healthy volunteers. The follow-up durations were limited in nearly all of the evidence, reflecting the acute nature of the illness. Study observation periods typically ranged from a single dose up to a maximum of 5 days; research exploring extended or long-term symptom patterns is scarce. The results apply only to the populations studied and reflect the specific conditions under which they were conducted, such as the very short-term, acute research scenarios.

What is Still Uncertain About the Research Base

There are notable limitations and uncertainties in the research landscape. For the specific fixed-dose combination containing Ascorbic Acid, dedicated trials may be limited compared to older combinations that included an antihistamine instead. Furthermore, the effectiveness of one core component—orally administered phenylephrine (the decongestant)—has been subject to significant public regulatory scrutiny. Scientific review by authoritative bodies research describes trials that have provided inconsistent evidence, meaning that certainty remains low regarding its impact on nasal congestion when taken orally. Research has not fully established the role of the phenylephrine component in the context of the other active ingredients; its contribution to the congestion relief axis of the combination was observed in some studies and remains subject to scientific regulatory scrutiny.

How should Corenza C be stored and disposed of?

How to Store and Dispose of Corenza C

The storage and disposal instructions for Corenza C are defined by regulatory authorities to ensure product stability and safety. The medicine must be stored in a cool place at or below 25, C.

Storage Requirements

The product must be kept in its original container and protected from moisture and light; it is prohibited to store Corenza C in a high-humidity environment such as a bathroom. The medicine must always be stored out of reach of children.

Disposal Requirements

To dispose of the product safely, do not use Corenza C after the expiry date stated on the label. Unused or expired medicine must be returned to a pharmacist for proper disposal and must not be thrown into drains or sewerage systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Corenza C found in:

A-Z Index: